JPS60105620A - 尿アルカリ化剤組成物 - Google Patents
尿アルカリ化剤組成物Info
- Publication number
- JPS60105620A JPS60105620A JP21478583A JP21478583A JPS60105620A JP S60105620 A JPS60105620 A JP S60105620A JP 21478583 A JP21478583 A JP 21478583A JP 21478583 A JP21478583 A JP 21478583A JP S60105620 A JPS60105620 A JP S60105620A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- urine
- citric acid
- sodium citrate
- ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- 210000002700 urine Anatomy 0.000 title claims abstract description 44
- 230000003113 alkalizing effect Effects 0.000 title claims description 17
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 90
- 239000001509 sodium citrate Substances 0.000 claims abstract description 29
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims abstract description 29
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims abstract description 28
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims abstract description 26
- 235000019797 dipotassium phosphate Nutrition 0.000 claims abstract description 26
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000007787 solid Substances 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 230000037351 starvation Effects 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 239000011734 sodium Substances 0.000 abstract description 5
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 206010020772 Hypertension Diseases 0.000 abstract description 3
- 230000003355 alkalizing urine Effects 0.000 abstract 1
- 239000003792 electrolyte Substances 0.000 abstract 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 11
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 11
- 229940116269 uric acid Drugs 0.000 description 11
- 241000700159 Rattus Species 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 4
- 239000001508 potassium citrate Substances 0.000 description 4
- 229960002635 potassium citrate Drugs 0.000 description 4
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 4
- 235000011082 potassium citrates Nutrition 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000009911 Urinary Calculi Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000021962 pH elevation Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008085 renal dysfunction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- -1 sodium citrate potassium hydrogen diphosphate Chemical compound 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-N sodium;hydron;carbonate Chemical compound [Na+].OC(O)=O UIIMBOGNXHQVGW-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21478583A JPS60105620A (ja) | 1983-11-15 | 1983-11-15 | 尿アルカリ化剤組成物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21478583A JPS60105620A (ja) | 1983-11-15 | 1983-11-15 | 尿アルカリ化剤組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS60105620A true JPS60105620A (ja) | 1985-06-11 |
| JPH0430374B2 JPH0430374B2 (cs) | 1992-05-21 |
Family
ID=16661492
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21478583A Granted JPS60105620A (ja) | 1983-11-15 | 1983-11-15 | 尿アルカリ化剤組成物 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS60105620A (cs) |
-
1983
- 1983-11-15 JP JP21478583A patent/JPS60105620A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0430374B2 (cs) | 1992-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPH0535130B2 (cs) | ||
| JP3038456B2 (ja) | ジデオキシプリンヌクレオシドの改良された経口投与処方物 | |
| Haldane et al. | The effect of reaction changes on human inorganic metabolism | |
| JPH05306221A (ja) | 腸管洗浄液用組成物及び腸管洗浄液 | |
| US3865935A (en) | Tableting of erythromycin base | |
| KR100966977B1 (ko) | 항생 활성을 갖는 약제 조성물 | |
| AU2006270162B2 (en) | A powder mix of potassium calcium citrate for the treatment of kidney stones and osteoporosis | |
| AU602899B2 (en) | Treatment of hypertension, compounds and compositions for antihypertension and diuresis | |
| Umeki et al. | Supplemental fosfomycin and/or steroids that reduce cisplatin-induced nephrotoxicity | |
| Orme et al. | The effects of long term administration of dopamine on renal function in hypertensive patients | |
| SU1009467A1 (ru) | Средство дл растворени мочевых конкрементов | |
| Pearson et al. | The Pathophysiology of Congential Chloridorrhoea | |
| EP0022429B1 (en) | Process for the preparation of gastric acid neutralizing agents and gastric acid neutralizing agents | |
| BG60901B1 (bg) | Гранулат,съдържащ натриев 2-меркаптоетансулфонаткато активно вещество и метод за получаването му | |
| JPS60105620A (ja) | 尿アルカリ化剤組成物 | |
| WO2022042450A1 (zh) | 三羟甲基氨基甲烷药学可接受的盐在治疗高尿酸血症药物中的应用 | |
| JPS60197624A (ja) | 尿アルカリ化性食品組成物 | |
| US4098883A (en) | Aluminum compound and pharmaceutical compositions containing same | |
| EP0443028B1 (en) | Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer | |
| JPS60105619A (ja) | 尿アルカリ化性食品組成物 | |
| JPS60197623A (ja) | 尿アルカリ化剤組成物 | |
| CN106580938A (zh) | 一种氨丁三醇有机酸盐及其制备方法和应用 | |
| US3055805A (en) | Process of treating acidosis with t.h.a.m. | |
| US4271150A (en) | Urokinase preparation for oral administration | |
| JPS59144741A (ja) | ホパンテン酸カルシウム組成物 |